Experience with the use of blinatumomab in acute lymphoblastic leukemia in children (clinical case)

Evaluation of the effectiveness of blinatumomab in acute lymphoblastic leukemia in children. The material for the study was patient N., 16 years old, who was admitted on March 10, 2022 for inpatient examination and treatment in the 1st children's department at the Children's Center for Hematology, Oncology and Clinical Immunology (DСGOСI, Uzbekistan, Tashkent), where diagnosis of acute lymphoblastic leukemia based on a set of data from clinical and laboratory studies. Comprehensive standard clinical, laboratory and instrumental studies were conducted. The study showed that after the use of the drug blinatumomab ("blincyto") in ALL, it is possible to achieve a complete clinical and hematological remission of the disease.